Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout: filing

Looking to bolster Sanofi's portfolio of marketed drugs and pipeline prospects, CEO Paul Hudson went on a dealmaking spree last year. That included the drugmaker's $1.9 billion buyout of Kadmon, where more than two dozen staffers are now losing their jobs.